Pulmonary hypertension (PH) is a complex, multifaceted disease that influences numerous patients globally. Substantial progress has been observed in the understanding of PH's pathophysiology over the last decade thanks to multiple dedicated studies. However, it remains a grave condition due to the lack of early diagnosis and effective treatment options,...
Discover more insightsThe market for Pulmonary Arterial Hypertension (PAH) drugs is modulated by several factors, both on the demand and supply side. Rising global incidence of PAH coupled with increased awareness, enhanced diagnostic methodologies and improved availability of treatments are fueling demand. From the supply perspective, new market entrants and novel therapy...
Discover more insightsPresently, advancements in pharmaceuticals targeting high blood pressure in the lungs, also known as Pulmonary Arterial Hypertension (PAH), are predominantly geared towards enhancing patient survival rates and improving quality of life. Recent additions to the pharmaceutical market have focused on combination drug therapies, exhibiting a broad and positive shift in...
Discover more insights